via: news92fm.com
Patients who have been diagnosed with HER2-positive breast cancer may be eligible for a clinical study led by Baylor College of Medicine. The multi-institutional research will evaluate a new method of treatment that combines HER2-targeted therapies and excludes chemotherapy.
The study is a follow-up to a recent clinical trial that showed HER2-positive breast cancer patients using trastuzumab (Herceptin) and lapatinib (Tykerb) for 12 weeks – without chemotherapy. Patients reportedly showed a significant benefit in the eradication of breast cancer tumors. The data was released in May 2011 by the



![Is Tyler Perry Gay? Ex-Friend Outs Him, Then Gets Jumped [VIDEO + POLL]](http://ronemyhoustonmajic.files.wordpress.com/2012/04/tylerperryview.jpg?w=144)


![Live After 5 R&B Edition Recap [WATCH]](http://ronemyhoustonmajic.files.wordpress.com/2013/05/screen-shot-2013-05-20-at-1-44-34-pm.png?w=157)




























